LabCorp 2008 Annual Report Download - page 16

Download and view the complete annual report

Please find page 16 of the 2008 LabCorp annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 58

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58

Outcome
Improvement
Programs
To say the need for improved outcomes
in CKD is signifi cant would be an understate-
ment. CKD affects more than 26 million
Americans, many of whom are not aware
that they have reduced kidney function, even
in later stages of the disease. CKD treatment
in these stages costs an estimated $37 billion
annually. With proper treatment, however,
disease progression, related deaths and
expense can be greatly reduced.
LabCorp’s CKD program helps to identify
patients with reduced kidney function, offers
physicians a sophisticated decision support
CellaVision® automated cell locating device: Computer-coupled
optics enhances rigorous analysis of cell morphology critical to
accurate diagnostic information. The CellaVision® technology allows
the technologist to view digital images, rather than using a microscope
and screening the stained slides manually.
tool, and provides clinicians with outcome
reporting and services to ensure continued
patient progress. Developed by a team
of international experts, LabCorp’s CKD
program is based on the National Kidney
Foundation’s Kidney Disease Outcome
Quality Initiative. As we grow and further
develop this fi rst-of-its-kind program, we are
building a model upon which future outcome
improvement programs can be based.
14 Laboratory Corporation of America® Holdings 2008
Chronic disease management often requires
daily and highly vigilant individualized care
that can quickly overburden even the best
health care infrastructure. Our outcome
improvement programs provide patient-
specific clinical guidance that can
dramatically improve outcomes, while also
reducing the cost and time associated with
treating chronic disease care. The positive
reception to our Litholink Kidney Stone
prevention model has provided a natural
expansion path into chronic kidney
disease (CKD).